<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>11809145</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Pereira, José Luis</dc:author>
<dc:author>López-Pardo, Francisco</dc:author>
<dc:author>Astorga, Ricardo</dc:author>
<dc:author>García-Luna, Pedro Pablo</dc:author>
<dc:author>Rodríguez-Puras, María José</dc:author>
<dc:author>Parejo, Juana</dc:author>
<dc:description xml:lang="en">BACKGROUND Some anorectic drugs have been related with he development of heart valve lesions. Sibutramine is a new anorectic drug used for the treatment of obesity. Although data reported to date suggest that sibutramine does not induce heart valve lesions, there are no published reports performing longitudinal echocardiographic studies before and after treatment with sibutramine. PATIENTS AND METHODS Consecutive series of 16 obese patients who underwent Doppler-echocardiography before and after treatment with sibutramine. RESULTS After 6 months of treatment, at 10 mg/day dose, sibutramine does noe appear to induce heart valve lesions. CONCLUSIONS Sibutramine does not induce heart valve lesions when it is used in short-term treatment courses.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2002 Jan 26 </dc:date>
<dc:title xml:lang="es">Estudio de la función valvular cardíaca en pacientes obesos tratados con sibutramina.</dc:title>
<dc:title xml:lang="en">[Study of heart valve function on obese patients treated with sibutramine].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
